Real Time, Automated Singlet Oxygen Dosimeter for PDT
用于 PDT 的实时、自动单线态氧剂量计
基本信息
- 批准号:7272152
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2008-07-31
- 项目状态:已结题
- 来源:
- 关键词:Actinic keratosisAge related macular degenerationAnimalsAreaBiologicalBladderBorderline Personality DisorderBrainBronchopulmonary DysplasiaCalibrationCancerousClinicalClinical ResearchClinical TrialsCollaborationsCompatibleComputer softwareConditionCoupledDataDatabasesDetectionDevelopmentDevice ApprovalDevicesDiscriminationDisease regressionDoseEffectivenessElementsEsophagealEvaluationFiberFoundationsGeneral HospitalsGoalsGovernmentGrantHandHumanImplantIn VitroInfusion proceduresKnowledgeLasersLearningLettersLicensingMalignant NeoplasmsMalignant neoplasm of lungMarketingMassachusettsMeasurementMethodsModalityModelingMolecularMonitorMusNecrosisNeoplasm MetastasisNoiseNumbersOperative Surgical ProceduresOutcomeOutcome MeasureOxygenPerformancePersonsPharmaceutical PreparationsPharmacologic SubstancePhasePhase II Clinical TrialsPhotochemotherapyPhotosensitizing AgentsPrimary NeoplasmProcessProstatic NeoplasmsProteinsProtocols documentationPurposeRangeRattusReactionResearchResearch PersonnelSafetySalesSamplingScoreSeriesSignal TransductionSinglet OxygenSkinSmall Business Funding MechanismsSmall Business Innovation Research GrantSolutionsStatistically SignificantStudy SectionSystemTestingTimeTreatment outcomeUnited States Food and Drug AdministrationUnited States National Institutes of HealthValidationVendorVisible RadiationWorkaqueousbasecancer cellcancer therapyclinical applicationcollegecommercializationdata acquisitiondesigndetectordosimetryhuman studyhuman subjectimprovedin vivointerestkillingslight intensitynext generationphysical sciencepre-clinicalpreclinical studyprognosticprogramsprototyperesearch studysensorsuccesstooltumorusability
项目摘要
DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) is a relatively new, rapidly developing, and promising modality for cancer treatment. PDT uses certain compounds known as photosensitizers (PS's) that are preferentially retained in malignant tumors. With visible light, the photosensitizers initiate a reaction that selectively kills the malignant cells to which they are attached. FDA approval has been granted for treatment of esophageal and certain lung cancers. PDT is being used in clinical trials for bladder, brain, skin and other cancers. PDT is also being applied to important areas outside of cancer treatment including age related macular degeneration and actinic keratosis, a pre-cancerous skin condition. There is considerable evidence that singlet molecular oxygen (O2(a1?)) is the active species in cancer cell necrosis. A real-time dosimeter for singlet oxygen produced during PDT would be a valuable tool for better understanding the PDT process and for improving treatment outcomes. The overall objective of the proposed SBIR Fast Track program is to build upon our recent success in developing a prototype, real-time detector for singlet oxygen to complete focused, but extensive pre-clinical studies. In Phase I we will significantly improve the sensitivity of the sensor and quantitatively demonstrate these improvements in a series of in-vitro and in-vivo studies. In Phase II we will incorporate the lessons learned in Phase I and build an upgraded, fieldable version and deliver it to the Massachusetts General Hospital (MGH) for an extensive series of animal and human studies. One critical study will be to demonstrate the quantitative relationship between PDT treated tumor regression and the amount of singlet oxygen produced during the treatment. Carefully constructed protocols for the animal studies will examine important PDT parameters including PS type and concentration, light intensity and total dose, and the time between PS infusion and PDT treatment. These studies will use only FDA approved photosensitizers (ALA and BPD) to maximize the relevance of the results to PDT in humans. Near the end of the three year program, MGH will complete a study of PDT generated singlet oxygen from healthy human subjects with topical ALA on their skin. The Fast Track program will result in a robust and statistically significant data base that will be submitted to the FDA at the end of the program. The goal is to obtain FDA approval to market the singlet oxygen monitor to PDT researchers as the initial target market. This program will be relevant to an emerging form of cancer therapy and will provide validation of a real-time sensor that has the potential to improve PDT treatment outcomes. PDT is a growing and promising modality, and the results of this project will not only provide important data that could improve treatment outcomes, but also facilitate FDA approval of the device so it would be available to more researchers with the goal of advancing PDT.
描述(由申请人提供):光动力疗法(PDT)是一种相对较新、发展迅速且有前景的癌症治疗方式。 PDT 使用某些称为光敏剂 (PS) 的化合物,这些化合物优先保留在恶性肿瘤中。利用可见光,光敏剂会引发反应,选择性地杀死它们所附着的恶性细胞。 FDA 已批准用于治疗食道癌和某些肺癌。 PDT 正在用于膀胱癌、脑癌、皮肤癌和其他癌症的临床试验。 PDT 还应用于癌症治疗以外的重要领域,包括年龄相关性黄斑变性和光化性角化病(一种癌前皮肤病)。有大量证据表明单线态分子氧 (O2(a1?)) 是癌细胞坏死的活性物质。 PDT 期间产生的单线态氧的实时剂量计将是更好地了解 PDT 过程和改善治疗结果的宝贵工具。拟议的 SBIR 快速通道计划的总体目标是建立在我们最近成功开发单线态氧实时检测器原型的基础上,以完成有重点但广泛的临床前研究。在第一阶段,我们将显着提高传感器的灵敏度,并在一系列体外和体内研究中定量证明这些改进。在第二阶段,我们将结合第一阶段的经验教训,构建一个升级的、可现场使用的版本,并将其交付给马萨诸塞州总医院 (MGH) 进行一系列广泛的动物和人类研究。一项关键研究将证明 PDT 治疗的肿瘤消退与治疗期间产生的单线态氧量之间的定量关系。精心构建的动物研究方案将检查重要的 PDT 参数,包括 PS 类型和浓度、光强度和总剂量,以及 PS 输注和 PDT 治疗之间的时间。这些研究将仅使用 FDA 批准的光敏剂(ALA 和 BPD),以最大限度地提高结果与人类 PDT 的相关性。在三年计划即将结束时,麻省总医院将完成一项 PDT 产生的单线态氧的研究,该研究是在皮肤上局部使用 ALA 的健康人体受试者身上产生的。快速通道计划将产生一个强大且具有统计意义的数据库,该数据库将在计划结束时提交给 FDA。目标是获得 FDA 批准,将单线态氧监测仪作为最初的目标市场销售给 PDT 研究人员。该计划将与一种新兴的癌症治疗方式相关,并将提供对有潜力改善 PDT 治疗结果的实时传感器的验证。 PDT 是一种不断发展且前景广阔的治疗方式,该项目的结果不仅将提供可以改善治疗结果的重要数据,还将促进 FDA 批准该设备,以便更多研究人员能够使用该设备,以推进 PDT。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN J DAVIS其他文献
STEVEN J DAVIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN J DAVIS', 18)}}的其他基金
Real Time, Automated Singlet Oxygen Dosimeter for PDT
用于 PDT 的实时、自动单线态氧剂量计
- 批准号:
7937338 - 财政年份:2009
- 资助金额:
$ 15万 - 项目类别:
Real Time, Automated Singlet Oxygen Dosimeter for PDT
用于 PDT 的实时、自动单线态氧剂量计
- 批准号:
7666861 - 财政年份:2008
- 资助金额:
$ 15万 - 项目类别:
Real Time, Automated Singlet Oxygen Dosimeter for PDT
用于 PDT 的实时、自动单线态氧剂量计
- 批准号:
7659717 - 财政年份:2008
- 资助金额:
$ 15万 - 项目类别:
Singlet Oxygen Detector for Photodynamic Therapy
用于光动力治疗的单线态氧检测器
- 批准号:
6804565 - 财政年份:2002
- 资助金额:
$ 15万 - 项目类别:
Singlet Oxygen Detector for Photodynamic Therapy
用于光动力治疗的单线态氧检测器
- 批准号:
6690667 - 财政年份:2002
- 资助金额:
$ 15万 - 项目类别:
LASER-INDUCED PHOTOEMISSIVE IDENTIFICATION OF CALCULI
结石的激光诱导光透射识别
- 批准号:
3495839 - 财政年份:1989
- 资助金额:
$ 15万 - 项目类别:
相似海外基金
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
- 批准号:
10102692 - 财政年份:2024
- 资助金额:
$ 15万 - 项目类别:
EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
- 批准号:
10639785 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
- 批准号:
23K09052 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
- 批准号:
10642988 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
- 批准号:
10635325 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
- 批准号:
10584110 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
- 批准号:
22H03243 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
- 批准号:
10433610 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
- 批准号:
10504138 - 财政年份:2022
- 资助金额:
$ 15万 - 项目类别: